ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma

Yoshihiro Ohishi, Yoshinao Oda, Takeshi Uchiumi, Hiroaki Kobayashi, Toshio Hirakawa, Shingo Miyamoto, Naoko Kinukawa, Hitoo Nakano, Michihiko Kuwano, Masazumi Tsuneyoshi

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Purpose: The purpose of this study is to attempt to characterize patients with unfavorable clinical outcome by the relative mRNA levels of ABC transporter expression in their tumor samples and to examine whether relative mRNA levels of each of the ABC transporters can be a useful predictor of progression-free survival in advanced ovarian carcinoma. Experimental Design: We examined tumor samples taken from 30 patients with primary serous papillary adenocarcinoma of the ovary for the expression of MDR1 and MRP1, MRP2, and MRP3 mRNA by using real-time reverse transcription-PCR, and we evaluated its correlation with clinical outcome. All 30 patients were divided into three groups according to clinical outcome after debulking surgery and platinum-based chemotherapy: 8 patients were classified into the unfavorable group; 11 were classified into the favorable group; and 11 were classified into intermediate group. Results: The relative mRNA levels of MRP1 and MRP3 were significantly different among the three groups, and the mRNA levels of MRP1 and MRP3 in the unfavorable group were significantly higher than those in the favorable group by multiple comparison. The relative mRNA levels of MRP1 expression were significantly correlated with those of MRP3 expression. In the 30 patients with serous papillary adenocarcinoma, univariate and multivariate analysis demonstrated that the high relative mRNA levels of MRP1 expression were significantly correlated with a short period of progression-free survival.Conclusions: In patients with advanced ovarian serous papillary adenocarcinoma, these results suggest that patients with an unfavorable clinical outcome are characterized by increased levels of coordinated MRP1 and MRP3 mRNA expression in their tumor samples. Furthermore, a higher level of MRP1 mRNA expression can be a candidate for a useful predictor of a shorter period of progression-free survival.

Original languageEnglish
Pages (from-to)3767-3775
Number of pages9
JournalClinical Cancer Research
Volume8
Issue number12
Publication statusPublished - Dec 1 2002

Fingerprint

ATP-Binding Cassette Transporters
Carcinoma
Gene Expression
Messenger RNA
Papillary Adenocarcinoma
Disease-Free Survival
Neoplasms
Platinum
Reverse Transcription
Ovary
Research Design
Multivariate Analysis
Drug Therapy
Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Ohishi, Y., Oda, Y., Uchiumi, T., Kobayashi, H., Hirakawa, T., Miyamoto, S., ... Tsuneyoshi, M. (2002). ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma. Clinical Cancer Research, 8(12), 3767-3775.

ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma. / Ohishi, Yoshihiro; Oda, Yoshinao; Uchiumi, Takeshi; Kobayashi, Hiroaki; Hirakawa, Toshio; Miyamoto, Shingo; Kinukawa, Naoko; Nakano, Hitoo; Kuwano, Michihiko; Tsuneyoshi, Masazumi.

In: Clinical Cancer Research, Vol. 8, No. 12, 01.12.2002, p. 3767-3775.

Research output: Contribution to journalArticle

Ohishi, Y, Oda, Y, Uchiumi, T, Kobayashi, H, Hirakawa, T, Miyamoto, S, Kinukawa, N, Nakano, H, Kuwano, M & Tsuneyoshi, M 2002, 'ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma', Clinical Cancer Research, vol. 8, no. 12, pp. 3767-3775.
Ohishi, Yoshihiro ; Oda, Yoshinao ; Uchiumi, Takeshi ; Kobayashi, Hiroaki ; Hirakawa, Toshio ; Miyamoto, Shingo ; Kinukawa, Naoko ; Nakano, Hitoo ; Kuwano, Michihiko ; Tsuneyoshi, Masazumi. / ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma. In: Clinical Cancer Research. 2002 ; Vol. 8, No. 12. pp. 3767-3775.
@article{c4cbe050e5a645b59cfdc370901c6df6,
title = "ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma",
abstract = "Purpose: The purpose of this study is to attempt to characterize patients with unfavorable clinical outcome by the relative mRNA levels of ABC transporter expression in their tumor samples and to examine whether relative mRNA levels of each of the ABC transporters can be a useful predictor of progression-free survival in advanced ovarian carcinoma. Experimental Design: We examined tumor samples taken from 30 patients with primary serous papillary adenocarcinoma of the ovary for the expression of MDR1 and MRP1, MRP2, and MRP3 mRNA by using real-time reverse transcription-PCR, and we evaluated its correlation with clinical outcome. All 30 patients were divided into three groups according to clinical outcome after debulking surgery and platinum-based chemotherapy: 8 patients were classified into the unfavorable group; 11 were classified into the favorable group; and 11 were classified into intermediate group. Results: The relative mRNA levels of MRP1 and MRP3 were significantly different among the three groups, and the mRNA levels of MRP1 and MRP3 in the unfavorable group were significantly higher than those in the favorable group by multiple comparison. The relative mRNA levels of MRP1 expression were significantly correlated with those of MRP3 expression. In the 30 patients with serous papillary adenocarcinoma, univariate and multivariate analysis demonstrated that the high relative mRNA levels of MRP1 expression were significantly correlated with a short period of progression-free survival.Conclusions: In patients with advanced ovarian serous papillary adenocarcinoma, these results suggest that patients with an unfavorable clinical outcome are characterized by increased levels of coordinated MRP1 and MRP3 mRNA expression in their tumor samples. Furthermore, a higher level of MRP1 mRNA expression can be a candidate for a useful predictor of a shorter period of progression-free survival.",
author = "Yoshihiro Ohishi and Yoshinao Oda and Takeshi Uchiumi and Hiroaki Kobayashi and Toshio Hirakawa and Shingo Miyamoto and Naoko Kinukawa and Hitoo Nakano and Michihiko Kuwano and Masazumi Tsuneyoshi",
year = "2002",
month = "12",
day = "1",
language = "English",
volume = "8",
pages = "3767--3775",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma

AU - Ohishi, Yoshihiro

AU - Oda, Yoshinao

AU - Uchiumi, Takeshi

AU - Kobayashi, Hiroaki

AU - Hirakawa, Toshio

AU - Miyamoto, Shingo

AU - Kinukawa, Naoko

AU - Nakano, Hitoo

AU - Kuwano, Michihiko

AU - Tsuneyoshi, Masazumi

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Purpose: The purpose of this study is to attempt to characterize patients with unfavorable clinical outcome by the relative mRNA levels of ABC transporter expression in their tumor samples and to examine whether relative mRNA levels of each of the ABC transporters can be a useful predictor of progression-free survival in advanced ovarian carcinoma. Experimental Design: We examined tumor samples taken from 30 patients with primary serous papillary adenocarcinoma of the ovary for the expression of MDR1 and MRP1, MRP2, and MRP3 mRNA by using real-time reverse transcription-PCR, and we evaluated its correlation with clinical outcome. All 30 patients were divided into three groups according to clinical outcome after debulking surgery and platinum-based chemotherapy: 8 patients were classified into the unfavorable group; 11 were classified into the favorable group; and 11 were classified into intermediate group. Results: The relative mRNA levels of MRP1 and MRP3 were significantly different among the three groups, and the mRNA levels of MRP1 and MRP3 in the unfavorable group were significantly higher than those in the favorable group by multiple comparison. The relative mRNA levels of MRP1 expression were significantly correlated with those of MRP3 expression. In the 30 patients with serous papillary adenocarcinoma, univariate and multivariate analysis demonstrated that the high relative mRNA levels of MRP1 expression were significantly correlated with a short period of progression-free survival.Conclusions: In patients with advanced ovarian serous papillary adenocarcinoma, these results suggest that patients with an unfavorable clinical outcome are characterized by increased levels of coordinated MRP1 and MRP3 mRNA expression in their tumor samples. Furthermore, a higher level of MRP1 mRNA expression can be a candidate for a useful predictor of a shorter period of progression-free survival.

AB - Purpose: The purpose of this study is to attempt to characterize patients with unfavorable clinical outcome by the relative mRNA levels of ABC transporter expression in their tumor samples and to examine whether relative mRNA levels of each of the ABC transporters can be a useful predictor of progression-free survival in advanced ovarian carcinoma. Experimental Design: We examined tumor samples taken from 30 patients with primary serous papillary adenocarcinoma of the ovary for the expression of MDR1 and MRP1, MRP2, and MRP3 mRNA by using real-time reverse transcription-PCR, and we evaluated its correlation with clinical outcome. All 30 patients were divided into three groups according to clinical outcome after debulking surgery and platinum-based chemotherapy: 8 patients were classified into the unfavorable group; 11 were classified into the favorable group; and 11 were classified into intermediate group. Results: The relative mRNA levels of MRP1 and MRP3 were significantly different among the three groups, and the mRNA levels of MRP1 and MRP3 in the unfavorable group were significantly higher than those in the favorable group by multiple comparison. The relative mRNA levels of MRP1 expression were significantly correlated with those of MRP3 expression. In the 30 patients with serous papillary adenocarcinoma, univariate and multivariate analysis demonstrated that the high relative mRNA levels of MRP1 expression were significantly correlated with a short period of progression-free survival.Conclusions: In patients with advanced ovarian serous papillary adenocarcinoma, these results suggest that patients with an unfavorable clinical outcome are characterized by increased levels of coordinated MRP1 and MRP3 mRNA expression in their tumor samples. Furthermore, a higher level of MRP1 mRNA expression can be a candidate for a useful predictor of a shorter period of progression-free survival.

UR - http://www.scopus.com/inward/record.url?scp=0036898621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036898621&partnerID=8YFLogxK

M3 - Article

C2 - 12473588

AN - SCOPUS:0036898621

VL - 8

SP - 3767

EP - 3775

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 12

ER -